Sees Q1 adjusted EBTIDA $22M-$24M
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLBT:
- Cellebrite’s Strategic Positioning and Growth Potential: Buy Rating Affirmed
- Cellebrite announces its Government Cloud platform achieved FedRAMP designation
- Cellebrite price target raised to $28 from $24 at JPMorgan
- CLBT Upcoming Earnings Report: What to Expect?
- Cellebrite announces availability of GenAI capabilities within Guardian